Drug Safety-related Labeling Changes (SrLC) Database
| ANDA | Abbreviated New Drug Application |
| BLA | Biologics License Application |
| CDER | Center for Drug Evaluation and Research |
| MG | Medication Guide |
| NDA | New Drug Application |
| PCI | Patient Counseling Information |
| PI | Patient Information |
| PLR | Physician Labeling Rule |
| PLLR | Pregnancy and Lactation Labeling Rule |
| Italics |
For the most part, italics indicate an FDA comment such as:
Additions and/or revisions underlined These italics usually appear at the beginning of the section. In some cases, italics may be an inherent part of the label, and will most often appear in the body of the section. |
| Underlines | Any text that is underlined indicates text that has been added or revised. There are exceptions where underlining occurs in a section subtitle or heading. This is the case when there is just one word underlined in the body of the text. |
Sections
| BW | Box Warning |
| WP |
Warnings and Precautions all in one section (PLR-format) Warnings as one section (pre-PLR format) Precautions as one section (pre-PLR format) |
| AR | Adverse Reactions (in pre-PLR format, this may be a subheading under precautions). |
| DI | Drug Interactions (in pre-PLR format, this may be a subheading under precautions). |
| USP |
Use in Specific Populations (Inclusive on one or more of the following: Pregnancy; Lactation (PLLR- format); Nursing Mothers (pre-PLLR format); Females and Males of Reproductive Potential (PLLR format only); Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Sex, Race (these last six may be a subheading of precautions if label in pre-PLLR format. |
| PCI/PI/MG |
Patient Counseling Information (PLR format only) - summarizes the information that a health care provider should convey to a patient (or caregiver when applicable) when a counseling discussion is taking place (e.g., a physician prescribing a drug during an office visit, a nurse providing discharge instructions at a hospital, or a pharmacist conveying information at a pharmacy). Patient Information - FDA approved patient labeling. Medication Guide - paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events. |
Only NDAs and CDER regulated BLAs are included in this database. ANDAs are not included.
Applications that remain active, even if the product has been discontinued, undergo safety-related labeling changes.
KYBELLA (NDA-206333)
(DEOXYCHOLIC ACID)
Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)
09/11/2026 (SUPPL-6)
6 Adverse Reactions
6.2 Postmarketing Experience
Additions and/or revisions underlined:
The following adverse reactions have been identified during post-approval use of KYBELLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure.
Administration Site Conditions: injection site ulceration, necrosis, mass, infection, alopecia, and scarring.
…
09/11/2026 (SUPPL-7)
4 Contraindications
Additions and/or revisions underlined:
KYBELLA is contraindicated in patients with an infection in the injection area.
5 Warnings and Precautions
5.1 Marginal Mandibular Nerve Injury
Additions and/or revisions underlined:
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported in KYBELLA-treated patients during clinical trials. All marginal mandibular nerve injuries reported from the trials resolved without additional treatment (range 1-298 days, median 44 days). To avoid the potential for marginal mandibular nerve injury, do not inject KYBELLA into or in close proximity to the marginal mandibular branch of the facial nerve [see Dosage and Administration (2.3)].
5.2 Dysphagia
Additions and/or revisions underlined:
Difficulty swallowing (dysphagia) occurred in KYBELLA-treated patients in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia resolved without additional treatment (range 1-81 days, median 3 days).
Subjects with current or prior history of dysphagia were excluded from clinical trials.
Avoid use of KYBELLA in patients with a current or prior history of dysphagia because KYBELLA use may exacerbate the condition.
5.3 Injection Site Reactions
Subsection title revised
Additions and/or revisions underlined:
Injection Site Hematoma or Bruising
In clinical trials, 72% of subjects treated with KYBELLA had an injection site hematoma or bruising [see Adverse Reactions (6.1)].
Use KYBELLA with caution in patients with bleeding abnormalities (e.g., taking antiplatelet or anticoagulant therapy) as excessive bleeding or bruising in the treatment area may occur.
Injection Site Alopecia
Cases of injection site alopecia have been reported with KYBELLA administration. The onset and duration of this adverse reaction may vary among individuals and may persist.
Consider withholding subsequent KYBELLA treatments until resolution of this adverse reaction.
Injection Site Ulceration, Necrosis, Nodule, Mass, and Infection
Very superficial injections (into the dermis) of KYBELLA may result in skin ulceration and necrosis [see Dosage and Administration (2.3)]. Cases of injection site ulceration, necrosis, nodule (less than or equal to 3 cm in diameter), mass (> 3 cm in diameter), and infection have been reported with KYBELLA administration. Nodules or masses may occur following initial or subsequent KYBELLA administration. Some nodules and masses may not resolve and medical intervention may be required. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage.
Discontinue KYBELLA if patients develop injection site ulceration, necrosis, nodule, mass, or infection after KYBELLA administration.
5.4 Risk of Injecting in Proximity to Vulnerable Anatomic Structures
Newly added subsection:
To avoid potential tissue damage, do not inject KYBELLA into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
Avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.
5.5 Serious Adverse Reactions Associated with Unapproved Use Outside the Submental Region
Newly added subsection:
Serious adverse reactions have been reported following unapproved administration of KYBELLA outside the submental region (e.g., blurred or reduced vision with periorbital use, muscle or nerve injury including facial paresis and paresthesia). Cases of injection site nodules (less than or equal to 3 cm in diameter) and masses (> 3 cm in diameter) have also been reported following initial or subsequent administration of KYBELLA outside the submental region. The nodules and masses may not resolve and medical intervention may be required.
KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region [see Indications and Usage (1)].
6 Adverse Reactions
6.1 Clinical Trials Experience
Additions and/or revisions underlined:
…
Adverse reactions that lasted more than 30 days and occurred in more than 10% of KYBELLA-treated subjects were injection site numbness (42%), injection site edema/swelling (20%), injection site pain (16%), and injection site induration (13%).
8 Use in Specific Populations
8.4 Pediatric Use
Additions and/or revisions underlined:
Safety and effectiveness of KYBELLA have not been established in pediatric patients and KYBELLA is not recommended for use in children or adolescents.
8.5 Geriatric Use
Additions and/or revisions underlined:
The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT COUNSELING INFORMATIONAdditions and/or revisions underlined:
…
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients to contact their healthcare providers if they develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness) or difficulty swallowing, or if existing symptoms worsen [see Warnings and Precautions (5.1, 5.2)].
Advise patients to contact their healthcare providers if they develop injection site hematoma, brusing, alopecia, ulceration, necrosis, nodule, mass, infection, pain, numbness, induration, or paresthesia from the treatment area [see Warnings and Precautions (5.3)].
Additions and/or revisions underlined:
KYBELLA® (kye be lah) (deoxycholic acid) injection for subcutaneous use
What is KYBELLA?
KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”
The use of KYBELLA for the treatment of fat outside of the submental area is not recommended.
It is not known if KYBELLA is safe and effective in children under 18 years of age.
…
What are the
possible side effects of KYBELLA?
…
Injection site problems including:
…
nodules (less than or equal to 3 cm in diameter) or mass (> 3 cm in diameter). Some nodules and masses may not resolve, and medical treatment, may be required.
Infection
KYBELLA can cause serious side effects when injected into areas of the body other than below the chin (submental area) including:
blurred or reduced vision when injected around the eyes
muscle or nerve damage, including numbness and tingling in the face
lumps or nodules where the injection was given. These lumps or nodules may not resolve in time and medical treatment, may be required
…
10/05/2022 (SUPPL-5)
5 Warnings and Precautions
5.6 Injection site ulceration, necrosis, and infection
Additions and/or revisions underlined:
Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis [see Injection Technique (2.3)]. Cases of injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage. Do not administer KYBELLA into the affected area until complete resolution of the adverse reaction.
6 Adverse Reactions
6.2 Postmarketing Experience
Additions and/or revisions underlined:
The following adverse reactions have been identified during post-approval use of KYBELLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure.
Administration site conditions: injection site ulceration, necrosis, infection, alopecia, and scarring.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
17 PATIENT COUNSELING INFORMATION
Additions and/or revisions underlined:
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients to contact their healthcare providers if patients begin to develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or worsening of existing symptoms.
Advise patients to contact their healthcare providers for development of erythema, pain, open sore(s) or drainage from the treatment area.
05/20/2020 (SUPPL-2)
6 Adverse Reactions
6.2 Postmarketing Experience(Additions and/or revisions underlined)
The following adverse reactions have been identified during post-approval use of KYBELLA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA® exposure.
Administration site conditions: injection site ulceration, necrosis, alopecia, and scarring.
Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching.
Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia.
8 Use in Specific Populations
8.5 Geriatric Use(Additions and/or revisions underlined)
The clinical trials of KYBELLA® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT INFORMATION(Additions and/or revisions underlined)
…
Call your healthcare provider if you:
begin to develop weakness in the muscles of your face, or your smile becomes uneven
you have difficulty swallowing, or if any of the symptoms that you already have get worse
- develop open sores or drainage from the treatment area
The most common side effects of KYBELLA include:
swelling redness
pain areas of hardness in the treatment area
- numbness
These are not all of the possible side effects of KYBELLA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
…
05/20/2020 (SUPPL-3)
5 Warnings and Precautions
5.4 Risk of injecting in proximity to vulnerable anatomic structures(Additions and/or revisions underlined)
To avoid potential tissue damage, KYBELLA® should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.
6 Adverse Reactions
6.2 Postmarketing Experience(Additions and/or revisions underlined)
The following adverse reactions have been identified during post-approval use of KYBELLA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA® exposure.
Administration site conditions: injection site ulceration, necrosis, alopecia, and scarring.
Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching.
Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia.
Procedural Complications: Vascular injury due to inadvertent intravascular injection.
8 Use in Specific Populations
8.5 Geriatric Use(Additions and/or revisions underlined)
The clinical trials of KYBELLA® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT INFORMATION(Additions and/or revisions underlined)
…
What are the possible side effects of KYBELLA? KYBELLA can cause serious side effects, including:
Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness
Trouble swallowing
Injection site problems including:
a collection of blood under the skin (hematoma) or bruising
damage to an artery or vein if KYBELLA is inadvertently injected into it
hair loss
open sores (ulcers)
damage and tissue cell-death (necrosis) around the injection site
...
01/18/2018 (SUPPL-1)
4 Contraindications
(Additions and/or revisions are underlined)
KYBELLA® (deoxycholic acid) injection is contraindicated in the presence of infection at the injection sites.
5 Warnings and Precautions
5.1 Marginal mandibular nerve injury(Additions and/or revisions are underlined)
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA® (deoxycholic acid) injection should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve…
(Newly added subsection)
Cases of injection site alopecia have been reported with the administration of KYBELLA®. The onset and duration of this adverse reaction may vary among individuals and may persist. Consider withholding subsequent treatments until resolution of the adverse reaction.
(Newly added subsection)
Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with the administration of KYBELLA®. Do not administer KYBELLA® into the affected area until complete resolution of the adverse reaction.
6 Adverse Reactions
6.1 Clinical Trials Experience(Additions and/or revisions are underlined)
In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA® (deoxycholic acid) injection and 506 subjects were treated with placebo…
(Newly added subsection)
The following adverse reactions have been identified during post-approval use of KYBELLA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA® exposure.
Administration site conditions: injection site ulceration, necrosis and alopecia.
8 Use in Specific Populations
8.1 Pregnancy(Additions and/or revisions are underlined)
Risk Summary
There are no adequate and well-controlled studies of KYBELLA® (deoxycholic acid) injection in pregnant women to inform the drug-associated risk…
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
17 PATIENT COUNSELING INFORMATION(Additions and/or revisions are underlined)
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients to contact their healthcare providers if patients begin to develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or worsening of existing symptoms.
Advise patients to contact their healthcare providers for development of open sores(s) or drainage from the treatment area.
